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19 Purpose: Gastric and gastroesophageal adenocarcinomas repre-
20 sent the third leading cause of cancer mortality worldwide. Despite
21 significant therapeutic improvement, the outcome of patients with
22 advanced gastroesophageal adenocarcinoma is poor. Randomized
23 clinical trials failed to show a significant survival benefit in molec-
24 ularly unselected patients with advanced gastroesophageal adeno-
25 carcinoma treated with anti-EGFR agents.
26 Experimental Design: We performed analyses on four cohorts:
27 IRCC (570 patients), Foundation Medicine, Inc. (9,397 patients),
28 COG (214 patients), and the Fondazione IRCCS Istituto Nazionale
29 dei Tumori (206 patients). Preclinical trials were conducted in
30 patient-derived xenografts (PDX).
31 Results: The analysis of different gastroesophageal adenocarci-
32 noma patient cohorts suggests that EGFR amplification drives
33 aggressive behavior and poor prognosis. We also observed that
34 EGFR inhibitors are active in patients withEGFR copy-number gain
35 and that coamplification of other receptor tyrosine kinases orKRAS
36 is associated with worse response. Preclinical trials performed on
37 EGFR-amplified gastroesophageal adenocarcinoma PDX models
38 revealed that the combination of an EGFR mAb and an EGFR
39 tyrosine kinase inhibitor (TKI) was more effective than each
40 monotherapy and resulted in a deeper and durable response. In
41 a highly EGFR-amplified nonresponding PDX, where resistance to
42 EGFR drugs was due to inactivation of the TSC2 tumor suppressor,
43 cotreatment with the mTOR inhibitor, everolimus, restored sensi-
44 tivity to EGFR inhibition.
45 Conclusions: This study underscores EGFR as a potential ther-
46 apeutic target in gastric cancer and identifies the combination of an
47 EGFR TKI and a mAb as an effective therapeutic approach. Finally,
48 it recognizes mTOR pathway activation as a novel mechanism of
49 primary resistance that can be overcome by the combination of
50 EGFR and mTOR inhibitors.
51
52 Introduction
53 Gastric and gastroesophageal adenocarcinomas represent the third
54 leading cause of cancer-related deaths worldwide. Despite the intro-
55 duction of novel systemic treatment options, the outcome of patients
56 with metastatic gastroesophageal adenocarcinoma (mGEA) is still
57 extremely unsatisfactory, with median overall survival (OS) of less
58 than 12 months in most clinical trials (1).
60While the identification of specific molecular subtypes has had
61profound implications for targeted strategies in other malignancies, the
62same progress has only been partially realized for patients with mGEA.
63Trastuzumab and ramucirumab (targeting HER2 and VEGFR2, respec-
64tively) are theonly approved targeted agents inmGEA (2, 3),whereas the
65promising role of immune checkpoint inhibitors, such as pembrolizu-
66mab and nivolumab, still needs to be confirmed by randomized clinical
67trials (RCT) performed in properly selected patient subgroups.
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70 The molecular landscape of gastroesophageal adenocarcinoma has
71 been extensively described and the two main molecular classifica-
72 tions (4, 5) identified a disease subtype characterized by chromosomal
73 instability and amplification of receptor tyrosine kinases (RTK). EGFR
74 amplification has been reported in 3%–5% of gastroesophageal adeno-
75 carcinomas (4, 6), while other genetic alterations (such as point muta-
76 tions or translocations) are extremely uncommon. Several EGFR-
77 targeting drugs, comprising mAbs and tyrosine kinase inhibitors (TKI),
78 have been approved for the treatment ofmultiple tumor types, including
79 RASwild-typemetastatic colorectal cancer, head andneck squamous cell
80 carcinoma, andEGFR-mutated advancednon–small cell lung cancer (7).
81 Conversely, three phase III RCTs evaluating the addition of cetuximab,
82 panitumumab, or gefitinib to the standard of care in molecularly
83 unselected patients with advanced gastric or esophageal adenocarcino-
84 mas reported negative results (8–10). On the other hand, intriguingly,
85 experimental data obtained in gastroesophageal adenocarcinoma pre-
86 clinical models showed a positive correlation between cetuximab
87 response and high EGFR expression/amplification (11). Consistent with
88 these preclinical findings, the association between EGFR copy-number
89 gain (CNG) and better OS has been shown by a phase II trial of
90 cetuximab plus FOLFOX chemotherapy in patients with mGEA (12).
91 In addition, a prespecified subgroup analysis of the COG trial showed
92 that patients with esophageal and gastroesophageal junction carcinomas
93 bearing EGFR CNG derived a significant progression-free survival, OS,
94 and health-related quality of life benefit from gefitinib compared with
95 placebo, thereby providing the proof of concept for EGFR CNG as a
96 predictive biomarker of efficacy of EGFR-targeted agents (13).
97 Here, we aimed to investigate the efficacy of several EGFR inhibition
98 strategies in preclinical models of EGFR-amplified gastroesophageal
99 adenocarcinomas, to describe the clinical and molecular features of
100 patients with EGFR-amplified tumors and their responsiveness to
101 EGFR inhibition, and to extensively investigate common and poten-
102 tially novel genomic mechanisms of resistance, with the ultimate goal
103 to optimize EGFR-targeted combinations for the development of
104 future clinical trials.
105 Materials and Methods
106 Patients
107 IRCC
108 Tumor samples (from gastric and gastroesophageal junction ade-
109 nocarcinomas) and matched normal samples were obtained from
111patients undergoing surgery in 15 Italian hospitals: Candiolo Cancer
112institute- FPO, IRCCS (Torino, Italy), Ordine Mauriziano Hospital
113(Torino, Italy), San Giovanni Battista Hospital (Torino, Italy), San
114Luigi Gonzaga Hospital (Torino, Italy), Humanitas-IRCCS (Milano,
115Italy), San Raffaele Hospital (Milano, Italy), Treviglio-Caravaggio
116Hospital (Bergamo, Italy), Brescia Hospital (Brescia, Italy), Borgo-
117Trento Hospital (Verona, Italy), Santa Maria delle Scotte Hospital
118(Siena, Italy), Forli’ Hospital (Forli, Italy), Fondazione Macchi Hos-
119pital (Varese, Italy), Pisa Hospital (Pisa, Italy), Fondazione IRCCS
120Istituto Nazionale dei Tumori (Milano, Italy), and Ospedale Niguarda
121Ca’ Granda (Milano, Italy). All patients provided written informed
122consent; samples were collected and the study was conducted under
123the approval of the review boards of all the institutions. The study was
124performed in accordance with the principles of the Declaration of
125Helsinki, the International Conference on Harmonisation and Good
126Clinical Practice guidelines, and General Data Protection Regulation.
127Clinical and pathologic data were entered and maintained in our
128prospective database. All the samples were anonymized before being
129shipped to Candiolo. No reference to the patients can be inferred from
130the histologic and molecular characterization presented in the work.
131Foundation Medicine, Inc.
132Tumor samples from patients with gastroesophageal adenocarci-
133noma were submitted during routine clinical care for comprehensive
134genomic profiling (CGP). Approval for this study, including a waiver
135of informed consent and a Health Insurance Portability and Account-
136ability Act waiver of authorization, was obtained from the Western
137Institutional Review Board (protocol no. 20152817).
138Cell lines and drugs
139293T cells were obtained from the ATCC and OE21 from Sigma-
140Aldrich. The genetic identity of the cell lines was confirmed by short
141tandem repeat profiling (Cell ID, Promega). Erlotinib and everolimus
142were purchased from Carbosynth. Cetuximab and lapatinib were
143provided by the hospital pharmacy.
144Primary cell cultures and organoids
145Gastroesophageal adenocarcinoma primary cells were derived from
146patient-derived xenografts (PDX) as described in (14), while gastro-
147esophageal adenocarcinoma primary organoids were obtained as
148described in (15). The genetic identity of the in vitro–derived material
149with the original tumor was verified by short tandem repeat profiling
150(Cell ID, Promega). GTR0078 cells were used for the in vitro experi-
151ments soon after tumor dissociation, as they do not permanently grow
152in culture.
153Western blot analysis and immunoprecipitation
154Cells Q5/organoids were treated with the indicated drugs: 100 nmol/L
155lapatinib or erlotinib for 2hours and0.5mg/mLcetuximab for 16hours.
156Whole-protein extracts were prepared using Laemmli buffer and
157quantified using the BCA Protein Assay Kit (Pierce). EGFR immu-
158noprecipitation was performed with cetuximab on organoids (stim-
159ulated with 100 ng/mL EGF for 150, treated or not with erlotinib
160100 nmol/L for 2 hours) previously washed out fromMatrigel with Cell
161Recovery Solution (#354253, Corning) and lysed with EB (1% Triton,
16220 mmol/L Q6Tris-HCl pH 7.4, 5 mmol/L EDTA pH 8, 10% glycerol, and
163150 mmol/L NaCl). Primary antibodies, anti-EGFR (1005:sc-03) and
164anti-Actin, were from Santa Cruz Biotechnology, and antibodies against
165phosphorylated EGFR (Tyr 845), ERK (Thr202/Tyr204), phosphory-
166lated AKT (Ser473) (Clone D9E), total AKT, and ERK were from
167Cell Signaling Technology. Antibody against phosphorylated EGFR
Translational Relevance
Prior clinical trials performed in unselected patients with gas-
troesophageal adenocarcinoma failed to show survival improve-
ment upon treatment with anti-EGFR therapies. We report the
clinical activity of EGFR mAbs in patients bearing high level (>8
copies) of EGFR gene amplification, and show that in patient-
derived xenografts, the combination of an EGFR mAb and a
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pathway activation as a novel mechanism of resistance to EGFR-
targeted therapy and show that it can be overcome by the com-
bination of EGFR/mTOR inhibitors. These findings recognize
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170 (Tyr1068) (ab5644) was fromAbcam. Antibody directed against amino
171 acid 1,172–1,186 of human EGFR was described in (16). Antibody anti-
172 EGFR extracellular epitope (111.6 antibody) was from Thermo Fisher
173 Scientific. Secondary antibodies were from Amersham. Detection was
174 performed with ECL System (Amersham).
175 Transfection and transduction procedures
176 OE21 cells were transfected with siRNAs using Lipofectamine 2000
177 (Thermo Fisher Scientific). Transfection reagents plus siRNAs at final
178 concentration of 20 nmol/L were used following standard protocols.
179 Seventy-two hours after transfection, cells were lysed and Western
180 blotting was performed. TSC2 silencing was achieved by using
181 SMARTpool ON-TARGETplus siRNA (Dharmacon).
182 Lentiviruses were produced as described in (17). OE21 cells were
183 transduced with a pool of lentiviral particles containing of four TSC2
184 silencing short hairpin RNAs (shRNA; Sigma, #40179, #40178,
185 #40454, and #40455). Cells were selected with puromycin, checked
186 for TSC2 silencing, and subcutaneously injected in NOD/SCID mice
187 (5  106 cells/mouse) in 1:1 SF medium:Matrigel (Corning).
188 Analyte extraction
189 Genomic DNA was isolated using the Blood & Cell Culture DNA
190 Midi Kit (Qiagen). DNA concentrations were quantified using the
191 Qubit Fluorometer (Thermo Fisher Scientific).
192 Copy-number variation evaluation by qRT-PCR
193 Quantitative PCR experiments for estimation of EGFR, MET,
194 FGFR2, and KRAS copy-number variations (CNV) were performed
195 in triplicates using 2 ng total gDNA as a template, with the following
196 human TaqMan copy-number assays: for HER2 assay, ID
197 Hs02876245_cn; for EGFR assay, ID Hs04942325_cn; forMET assay,
198 ID Hs04993403_cn,; for FGFR2 assay, ID Hs01472955_cn; for KRAS
199 assay, ID Hs06936191; and the TaqMan Copy-number Reference
200 Assay RNase P 4316831 and GREB1 Hs01738470_cn (Applied Bio-
201 systems). PCR runs were performed with ABI Prism 7900HT (Applied
202 Biosystems).
203 AMNESIA panel
204 In a case–control study setting, we identified a panel of gene
205 alterations (including EGFR/MET/KRAS/PI3K/PTEN mutations and
206 EGFR/MET/KRAS amplifications) able to predict primary resistance
207 to trastuzumab therapy in patients with HER2-positive metastatic
208 gastric cancer (18). We applied the same panel of gene alterations
209 (substituting EGFR mutation/amplification with HER2 mutation/
210 amplification) in the context of EGFR-driven tumors.
211 Phospho-kinase array
212 Cells were treated with the indicated drugs: 100 nmol/L lapatinib or
213 erlotinib for 2 hours and 0.5 mg/mL cetuximab for 16 hours. The
214 analysis of the phosphorylation profiles of kinases was performed
215 using the Human Phospho-Kinase Antibody Array (R&D Systems),
216 according to themanufacturer’s instructions. Signal quantificationwas
217 performed using Image Lab 5.2.1 Software (Bio-Rad).
218 PDX generation
219 Gastric PDX generation was performed as described in (19). All
220 animal procedures adhered to the “Animal Research: Reporting of
221 In Vivo Experiments” standards and were approved by the Ethical
222 Commission of the Candiolo Cancer Institute (Torino, Italy) and by
223 the Italian Ministry of Health.
225PDX xenotrials
226PDXs were passaged and expanded for >2 generations until pro-
227duction of a cohort of mice. Established and randomized tumors
228(average volume, 250mm3)were treated for the indicated dayswith the
229following regimens (either single agent or combination): vehicle
230(saline) orally; cetuximab 20 mg/kg, i.p., twice weekly; lapatinib
231100 mg/kg, daily, orally; erlotinib 50 mg/kg, daily, orally; and ever-
232olimus 6mg/kg, daily, orally. Tumor size was evaluated once weekly by
233caliper measurements and approximate volume of the mass was
234calculated by using the formula 4/3p(D/2)(d/2)2, where d is the minor
235tumor axis and D is the major tumor axis. The response in mice was
236evaluated using RECIST 1.1–like criteria, that is, progressive disease
237(PD): ≥35% increase from baseline, partial response (PR): ≥50%
238reduction from baseline; and stable disease (SD): intermediate
239variations from baseline (20). Statistical testing for pharmacologic
240experiment was performed with GraphPad Prism software 8.0,
241using two-way ANOVA, followed by Bonferroni multiple compar-
242isons experiments. Statistical significance: ns, not significant;
243, P < 0.05; , P < 0.01; , P < 0.001.
244Genomic sequencing
245IRCC samples
246DNA extracted from PDX models along with a sample of normal
247germline DNA from each patient were utilized for next-generation
248sequencing. Using standard methods, Illumina sequencing libraries
249were generated and subjected to hybrid capture with a focused targeted
250bait set of 243 genes selected based upon their alteration in prior
251studies of gastroesophageal cancer (21, 22).
252Foundation Medicine, Inc. samples
253CGP was performed in a Clinical Laboratory Improvement
254Amendments–certified, New York State and College of American
255Pathologists–accredited laboratory [Foundation Medicine, Inc.
256(FMI)]. In brief, ≥50 ng DNA was extracted from 40 mm of
257formalin-fixed, paraffin-embedded (FFPE) tissue blocks from
2584,337 cases of gastric carcinoma. The samples were assayed by CGP
259using adaptor ligation and hybrid capture was performed for all coding
260exons of cancer-related genes from 180 to 395 plus select introns from
26114 to 34 genes frequently rearranged in cancer. Sequencing of captured
262libraries was performed to a mean exon coverage depth of >500, and
263resultant sequences were analyzed for genomic alterations, including
264mutations (base substitutions, insertions, and deletions), copy-number
265alterations (focal amplifications and homozygous deletions), and select
266gene fusions or rearrangements, as described previously (23). EGFR
267amplification was defined as EGFR copy ≥8.
268COG samples
269RTK copy numbers were determined using Affymetrix OncoScan
270CNV FFPE assay following the manufacturer’s recommended proto-
271col. DNA was extracted from histologically confirmed esophageal and
272gastroesophageal junction adenocarcinomas as described previous-
273ly (13) and quantified using the Quant-iT PicoGreen dsDNA Assay
274Kit (Life Technologies) following the manufacturer’s recommended
275protocol, using 80 ng for each case, normalized to a concentration
27612 ng/mL. Array fluorescence intensity data (CEL files), generated by
277Affymetrix GeneChip Command Console software version 4.0, were
278processed using OncoScan Console software version 1.1.034 to pro-
279duce OSCHP files and a set of QC metrics. Features were quantile
280normalized and genome-wide allele-specific copynumberwas assessed
281using the Affymetrix TuScan algorithm to allow adjustment for both
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284 tumor ploidy and nonaberrant cell admixture (24). Genome-wide
285 CNV was assessed across all cases using Affymetrix Nexus express
286 forOncoScan (version 3.1.). Significant CNV events across the genome
287 were identified using a “significance testing for aberrant copy number”
288 (STAC) approach (25).
289 The Fondazione IRCCS Istituto Nazionale dei Tumori samples
290 FFPE archivalQ7 tumor tissue blocks obtained prior to any treatment
291 were used for the purpose of this study. Next-generation sequencing
292 was performed, as in (26), to detect gene mutations, whereas EGFR,
293 HER2, and MET status was determined by SISH analysis and KRAS
294 GCN gain was assessed by PCR, as described previously in (18).
295 Survival analysis
296 OSwas calculated from the date of enrollment (for the COG trial) or
297 from the date of diagnosis of metastatic disease [for the Fondazione
298 IRCCS Istituto Nazionale dei Tumori (INT) dataset] until the date of
299 death or last follow-up for alive patients. The OS curves for EGFR-
300 amplified versus nonamplified subgroups were calculated with the
301 Kaplan–Meier method and compared with the log-rank test. Survival
302 analysis for COG was undertaken using IBM SPPS statistics 22, for
303 further details see (10, 13).
304 ISH and IHC
305 EGFR gene status was assessed by Bright-field Dual-color SISH
306 (VentanaMedical Systems). TheColorado scoring systemwas adopted
307 to classify samples into ISH strata according to the frequency of cells
308 with each EGFR gene copy number and referred to the chromosome 7
309 centromere. EGFR SISH–negative cases had no or low genomic gain
310 for EGFR gene copy number (disomy, low trisomy, high trisomy, and
311 low polysomy), whereas the distinction between high polysomy and
312 gene amplification was defined by the presence of gene clusters only in
313 EGFR-amplified cases. EGFR FISH in the COG cohort was performed
314 and scored as described in (13).
315 IHC for EGFR was performed using the CONFIRM anti-EGFR
316 (5B7) rabbit monoclonal primary antibody (Ventana Medical Sys-
317 tems) that recognizes the internal domain of EGFR and the mono-
318 clonal mouse anti-human anti-EGFR (E30) antibody (Dako) that
319 recognizes an external domain of EGFR. IHC was carried out on an
320 Automated Immunostainer (BenchMark Ultra; Ventana Medical
321 Systems) using the Optiview DAB Detection Kit (Ventana Medical
322 Systems). IHC for P-EGFR was performed using anti-P-EGFR Y1173
323 53AS from Cell Signaling Technology.
324 Transcriptome profiling
325 RNA sequencing (RNA-seq) libraries were prepared using the
326 Illumina TruSeq Stranded Total RNA Library Prep Gold kit and
327 sequenced generating 75 bp paired-end reads. PDX RNA-seq data
328 were first deconvoluted for mouse contamination with Xenome (27)
329 software (version 1.0.1). Nonhost reads (those classified as “graft,”
330 “ambiguous,” or “both”) were then mapped to UCSC hg38 reference
331 genome with HISAT2 (28) aligner with default parameters. Gene
332 expression estimate was performed with HTSeq (29) in “intersection-
333 nonempty” mode against GENCODE v33 annotation.
334 Results
335 Prevalence of EGFR amplification in patients with
336 gastroesophageal adenocarcinoma
337 We evaluated EGFR copy number in four different cohorts: (i) a
338 proprietary cohort (IRCC cohort) of 570 primary gastroesophageal
340adenocarcinomas (real-time PCR analysis), (ii) the FMI dataset of
3414,337 gastric and 5,060 esophageal/gastroesophageal junction adeno-
342carcinomas (CGP), (iii) the subgroup of 214 patients with esophageal
343or gastroesophageal junction adenocarcinoma enrolled in the COG
344trial (NCT01243398) of second-line gefitinib versus placebo (ref. 10;
345FISH), and (iv) the Fondazione IRCCS INT of Milan dataset of 206
346patients withmGEA (ISH and SISH). In the IRCC cohort we identified
34744 primary tumors (7.8%)withEGFRCNG(≥4 gene copies), with 10 of
348them (1.8% of all samples) bearing >8 gene copies (the suggested
349threshold of biologically meaningful amplification in the HER2 and
350MET context; ref. 30) and eight of them (1.4% of all samples) bearing a
351heterogeneous EGFR amplification (one tumor area >8 copies and one
352tumor area ≤8 copies; Fig. 1; Supplementary Table S1). In the FMI
353dataset, 3.4% of gastric and 7.6% of esophageal carcinomas showed
354EGFR amplification equal or higher than eight copies, while in the
355COGand INTdatasets, the frequencies ofEGFR amplificationwere 7%
356and 4.9%, respectively (Fig. 1). In both COG and INT cohorts, no
357significant association between EGFR amplification and baseline
358clinicopathologic characteristics was observed (Supplementary Tables
359S2 and S3).
360EGFR amplification drives aggressiveness and poor prognosis
361in gastroesophageal adenocarcinomas
362To investigate whether EGFR amplification is associated with poor
363prognosis of gastroesophageal adenocarcinomas, we took advantage of
364a cohort of pretreated patients with esophageal and gastroesophageal
365junction adenocarcinomas enrolled in the COG trial and randomized
366to placebo (10). Among 102 cases with available EGFR FISH status,
367patients with EGFR amplification had a significantly inferior median
368OS compared with those without EGFR amplification [3.1 vs.
3693.5 months; HR, 1.23; 95% confidence interval (CI), 1.03–1.48; P ¼
3700.026; Fig. 2A, left]. All patients with EGFR-amplified tumors died
371within 4 months.
372Similarly Q9, when focusing on the INT dataset, patients with EGFR
373amplification had inferior median OS as compared with those with
374EGFR SISH–negative tumors (17 vs. 18.9 months; HR, 1.95; 95% CI,
3750.90–4.21; P ¼ 0.083; Fig. 2A, right). These results have also been
376confirmed in primary gastric tumors by analyzing The Cancer
377Genome Atlas (TCGA) data, in which tumor EGFR amplification
378correlated with significantly inferior OS and DFS (Fig. 2B).
379Activity of EGFR inhibitors in patients with EGFR-amplified
380metastatic gastric cancer and landscape of primary treatment
381resistance
382To determine whether patients with EGFR-amplified mGEA may
383respond to EGFR inhibitors and to eliminate the potentially con-
384founding effect of the combination with chemotherapy, we focused on
385patients with EGFR-amplified mGEA treated at INT with the anti-
386EGFR mAb, panitumumab, as single agent after failure of standard
387treatment options. Three patients with EGFR amplification, confirmed
388by SISH, were identified (Supplementary Fig. S1A); their molecular
389profile is summarized in Supplementary Fig. S1B and their clinical
390history is reported in Fig. 3. Briefly, INT#1 patient had KRAS-
391coamplified mGEA and showed PD at the first radiological reassess-
392ment, INT#2 patient had no cooccurring alterations in HER2, MET,
393KRAS, or PIK3CA and showed a PR lasting 6 months, and INT#3
394patient had cooccurring heterogeneous KRAS amplification and
395showed a PR lasting only 10 weeks, followed by rapid clinical pro-
396gression and death.
397To verify whether RTK pathway activation is associated with
398EGFR inhibitor resistance in gastroesophageal adenocarcinoma, we
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401 investigated the relationship between RTK CNG and survival follow-
402 ing treatment with gefitinib in 12 EGFR FISH–positive gastroesoph-
403 ageal adenocarcinomas (seven with amplification and five with high
404 polysomy) of the COG trial. All 12 tumors analyzed had CNG (defined
405 as ≥4 gene copies) of at least one RTK (HER2, HER3, HER4, MET,
406 FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, PDGFR2, VEGFR1, VEGR2,
407 and VEGFR3). We found a significant inverse correlation between the
408 extent of coamplification of the RTKs and OS (Fig. 4A). This obser-
409 vation of shorter survival following gefitinib treatment with activation
410 of RTKs other than EGFR suggests optimizing inhibition of down-
411 stream signal transduction pathways could produce durable clinical
412 responses.
413 To investigate the prevalence of potential genetic predictors of
414 primary resistance to anti-EGFR treatment, we interrogated the TCGA
415 dataset for the presence of resistance alterations included in our
416 previously published AMNESIA panel (18) among cases with EGFR
417 amplification and showed the cooccurrence of other genomic events in
418 53% of samples (Supplementary Fig. S2). Finally, because the available
419 in silico datasets mainly represent a collection of primary gastroesoph-
420 ageal adenocarcinomas, we investigated the prevalence of AMNESIA
421 panel alterations in the 534 samples from patients with EGFR-ampli-
423fied mGEA included in the FMI dataset. This analysis showed the
424cooccurrence of other genomic events of interest in 186 (35%) samples
425(Fig. 4B).
426Dual EGFR blockade is the most effective treatment for EGFR-
427amplified PDXs
428Future Q10trials might be prompted to reassess the role of anti-EGFR
429mAbs and TKIs, either as monotherapy or in combination, in molec-
430ularly selected patients with gastroesophageal adenocarcinoma. As
431already shown for dualHER2 blockade (trastuzumab plus pertuzumab
432or lapatinib) in HER2-positive breast and colorectal cancer (31–33),
433and despite the partially negative phase III data recently reported with
434this strategy inHER2-positive gastric cancer (34), dual EGFR blockade
435strategies with an anti-EGFR mAb plus a TKI may be more effective
436than each drug as monotherapy.
437A large series of human cancer specimens transplanted into mice
438(PDX) produce a study population that can be randomized for
439prospective treatment with targeted agents and thus, provides a strong
440strategy to perform precision medicine preclinical studies. This
441approach brings together the plasticity of preclinical analysis with the
442informative value of population-based studies. From 570 gastric
Figure 1.
EGFR CNG. The graphs illustrate theQ8 percentage of tumors displaying EGFR CNG in four different cohorts. Real-time PCR analysis of IRCC gastric/gastroesophageal
junction (GEJ) adenocarcinomas displayingEGFR gain (4–8 copies ormore than eight copies) or heterogeneity (significantly different EGFRCNG in diverse analyzed
samples from the same tumor, with one tumor sample displaying >8 copies and one tumor sample having ≤8 copies). CGP of FMI gastric and esophageal/
gastroesophageal junction cases, FISH analysis of COG esophageal/gastroesophageal junction cases, and SISH analysis of INT gastric/gastroesophageal junction
adenocarcinomas.
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445 carcinoma samples (IRCC cohort), we generated a multi-level plat-
446 form of gastroesophageal adenocarcinoma models, comprising 151
447 PDXs, primary cell lines, and organoids (22). Despite conflicting
448 evidence on the CNG threshold clearly defining gene amplification,
449 preclinical and clinical data obtained from gastroesophageal adeno-
451carcinoma displaying HER2 or MET amplification suggested that the
452clinically relevant threshold is higher than eight gene copies (30, 35).
453Eleven PDXs harbored at least 4–8 EGFR copies and four PDXs had >8
454EGFR copies (Supplementary Fig. S3A, GTR0060:240 EGFR copies;
455GTR0078: 700 copies; GTR0110: 12 copies; and GTR0511: 80
Figure 2.
Survival analysis of patientswith EGFRCNG.A, The graphs show the cumulative survival (cum survival) of patients of the COG (left) and INT (right) cohorts related to
EGFR CNG. B, The graphs show the OS (left) and the disease-free survival (right) of patients of the gastroesophageal TCGA dataset, related to EGFR CNG.
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Figure 3.
Clinical history of patients treated with EGFR-targeted drugs. Summarized clinical course of INT patients with EGFR CNG. Red-lined boxes indicate periods of
administration of the indicated therapeutic agents. Blue vertical lines indicate timing of tumor specimen acquisition from surgical procedures or biopsies, as well as
dates of tumor assessment byCT scan. PD andSDaccording toRECIST 1.1. 5FU, 5-fluorouracil; CCDP, cisplatin, vinorelbine, ifosfamide, and epirubicin; EOX, epirubicin,
oxaliplatin, and capecitabine; FOLFIRI, folinic acid, 5-fluorouracil, and irinotecan; OGD, esophago-gastro-duodenoscopy; TCF, docetaxel, carboplatin, and
5-fluorouracil; XELOX, capecitabine and oxaliplatin.
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458 copies). These four models did not bear any other RTKs/KRAS CNV
459 >8 copies (data not shown). SISH analysis and IHC confirmed uniform
460 EGFR amplification and expression (Supplementary Fig. S3B). These
461 PDXmodels were expanded to generate cohorts ofmice to evaluate the
462 efficacy of the EGFR mAb, cetuximab, and the TKIs, erlotinib (EGFR
463 selective) and lapatinib (dual EGFR/HER2 inhibitor), as well as the
464 combination of the mAb with a TKI. The original tumors were serially
466passaged in vivo until 6 tumor-bearing animals were produced per
467experimental group. When xenografts reached an average tumor
468volume of approximately 250mm3, mice were randomized into six
469independent treatment cohorts: (i) vehicle (placebo), (ii) cetuximab,
470(iii) erlotinib, (iv) lapatinib, (v) cetuximab þ erlotinib, and (vi)
471cetuximab þ lapatinib. Tumor response was evaluated according to
472RECIST-like criteria (see Materials and Methods and figure legends).
Figure 4.
RTK/KRAS pathway activation in EGFR-amplified
cases. A, The scatter plot shows a significant
inverse correlation between the extent of RTKs
coamplification (HER2, HER3, HER4, MET, FGFR1,
FGFR2, FGFR3, FGFR4, IGF1R, PDGFR2, VEGFR1,
VEGR2, and VEGFR3 ≥4 gene copies) and OS in 12
EGFR FISH–positive gastroesophageal adenocar-
cinomas treatedwith gefitinib in the COG trial. Red
dots indicate cases with high polysomy and blue
dots represent cases with EGFR amplification. B,
The graph shows the cooccurrence of EGFR ampli-
fication and genomic events affecting the RTK/
KRAS pathway in EGFR-amplified gastroesopha-
geal adenocarcinoma tumors in the FMI dataset.
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475 As shown in Fig. 5A, the GTR0060 PDX (240 EGFR copies) did not
476 exhibit response to either of the TKIs used as monotherapy, but
477 showed PR upon cetuximab treatment. Notably, both the combination
478 (cetuximabþ TKIs) treatments resulted in a complete response (CR).
479 Interestingly, in 4 of 6 mice in the combination arms, including 3 of 3
480 mice treated with erlotinib þ cetuximab, the tumor mass did not
481 reappear even after more than 2 months of drug removal (Fig. 5B).
482 Improved efficacy of the combination treatment was observed at long
483 term also in a secondmodel, GTR0110, characterized by a lower EGFR
484 CNG (12 copies), uniformly distributed among tumor cells (Supple-
485 mentary Fig. S3B). While neither erlotinib nor lapatinib resulted in a
486 clinical response and cetuximab conferred disease stabilization, cetux-
487 imab plus TKI combination treatment resulted in a PR (Fig. 5C).
488 Moreover, at the end of the experiment, the tumor volume was
489 significantly reduced in mice treated with the combination compared
490 with those treated with the mAb alone. The xenotrial performed in the
491 GTR0511 PDX (80 EGFR copies) cohort also showed response to anti-
492 EGFR treatment. Even though neither cetuximab nor lapatinib mono-
493 therapies were effective, their combination resulted in a relevant
494 response. Interestingly, in this PDX, erlotinib was the only effective
495 monotherapy (Fig. 5D). To investigate the reason of the differential
496 sensitivity of GTR0511 to erlotinib, we analyzed whole-exome
497 sequencing data, but we did not detect EGFR alterations (data not
498 shown).On the contrary, RNA-seq analysis revealed a 10-fold decrease
499 of the number of reads covering the last portion of the receptor (from
500 exon 26 until the end of the mRNA; Supplementary Fig. S4A). This
501 resulted in the presence of an EGFR protein isoform lacking the
502 C-terminal domain, together with an EGFR full-length protein. As
503 Kovacs and colleagues (36) showed that the loss of this portion of the
504 tail, containing Y1068, determines a strong decrease in receptor
505 activation, we immunoprecipitated (with an antibody directed against
506 the EGFR extracellular portion) EGFR from organoids derived from
507 the three PDXs. As shown in Supplementary Fig. S4B, in GTR0511,
508 EGFR displayed only a modest activation, in spite of the high amount
509 of the expressed protein, meaning that the ratio between phosphor-
510 ylated/unphosphorylated receptor was much lower in GTR0511 com-
511 pared with the other amplified models. As predicted by in silico data,
512 two phosphorylated bands were detected only in GTR0511, and they
513 were both effectively inhibited by erlotinib. Finally, stronger down-
514 stream signal blockade in GTR0511 versus GTR0110 and GTR0060
515 was seen in total cell lysates derived from the same organoids. In
516 agreement with previously published data (36), we thus hypothesize
517 that the lack of the EGFR C-terminal tail in GTR0511 can be
518 responsible of its decreased activation and increased sensitivity to
519 erlotinib treatment.
520 To investigate which pathways were inactivated by the different
521 drugs/drug combinations in cases in which the combination resulted
522 in a strongly enhanced response, we took advantage of PDX-derived
523 primary cells in which EGFR amplification was maintained (Supple-
524 mentary Fig. S5A). Primary cells were treated with cetuximab, erlo-
525 tinib, and lapatinib, alone or in combination. Western blot analysis
526 showed that while lapatinib and erlotinib only slightly affected acti-
527 vation of downstream transducers, such as AKT, MAPK, and S6
528 (evaluated as read out of the PI3K, RAS/MAPK, andmTOR pathways,
529 respectively), a partial inhibition was induced by cetuximab. Interest-
530 ingly, both the dual combinations resulted in a strong inhibition of
531 signal transduction (Fig. 5E). Phospho-array analysis of cellular
532 kinases and RTKs confirmed these results, but did not identify any
533 other kinase specifically inhibited by the combination treatments
534 (Supplementary Fig. S5B). These in vitro data strongly support the
535 results we obtained in the in vivo experiments where cetuximab
537induced SD, while the two combinations resulted in a complete and
538durable response. It is thus likely that when EGFR activation is
539exceptionally intense, the dual blockade with TKI þ cetuximab is
540needed to improve the response.
541TSC2 inactivation is a mechanism of resistance to EGFR-
542targeted therapies
543We performed a preclinical trial, similar to those described previ-
544ously, using the GTR0078 PDX harboring approximately 700 EGFR
545copies (Supplementary Fig. S3). Despite the very high level of EGFR
546amplification, we did not observe response to the TKIs, nor to
547cetuximab or cetuximab þ TKI combination treatments (Fig. 6A).
548To understand the molecular basis for the observed resistance, we
549sequenced the tumor DNA and detected several genomic alterations;
550among these, we observed a fraction of EGFR gene copies displaying a
551deletion at the 50 gene portion, thus coding for a protein lacking the
552extracellular portion (Supplementary Fig. S6A). Moreover, we also
553observed two missense TSC2 mutations (p.M1300V and p.R1438Q),
554with an allelic frequency of 0.463 and 0.539, respectively (Fig. 6B). The
555TSC2 protein forms a complex with TSC1, a critical negative regulator
556of mTOR complex (mTORC) 1, which controls anabolic processes to
557promote cell growth (37–39). TSC2 inactivation (due to homozygous
558mutations or gene loss) results in increased mTOR activation (40).
559Interestingly, when we interrogated cBioPortal for the possible cooc-
560currence of EGFR and TSC2 functional genomic alterations in six
561gastric cancer datasets (4, 41–45), we found a significant correlation
562(Supplementary Fig. S6B). Moreover, alterations in the mTOR path-
563way cooccurrent with EGFR CNG have been identified in the FMI
564dataset as well, although cooccurrence with EGFR amplification was
565uncommon (Supplementary Fig. S6C).
566To support the causative role of TSC2 in EGFR target therapy
567resistance, we silenced TSC2 in OE21 cells, harboring EGFR gene
568amplification (46). In in vitro experiments, upon TSC2 silencing, we
569observed the constitutive activation of themTORpathway, revealed by
570the activation of the downstream transducer S6, whichwasmaintained
571even in the presence of anti-EGFR treatment (Supplementary
572Fig. S7A). To validate these data in vivo, we transduced OE21 cells
573with either control shRNA (shC) or a pool of TSC2 shRNAs and we
574injected them in immunocompromised mice. As shown in Supple-
575mentary Fig. S7B, shCmice underwent tumor regression in response to
576EGFR blockade, while partially TSC2-silenced tumors experienced
577only disease stabilization, reinforcing the idea that TSC2 silencing
578impairs the response to anti-EGFR therapy.
579We thus wondered whether treatment of GTR0078 tumors with an
580mTOR inhibitor (such as everolimus) could restore sensitivity to EGFR
581inhibitors. While treatment with everolimus alone did not show any
582clinical efficacy (Supplementary Fig. S6D), the combination of ever-
583olimus with erlotinib resulted in a significant clinical response
584(Fig. 6C). Experiments performed in PDX-derived cells showed that
585while treatment of GTR0078 cells with either EGFR inhibitors or
586everolimus was unable to block mTOR activation, the association of
587the two drugs resulted in a sustained inhibition of the pathway. Indeed,
588only the concomitant inhibition of the EGFR and mTOR pathway
589inactivated the downstream transducer S6 kinase (Fig. 6D).
590Discussion
591In unselected patients with advanced gastric/esophageal adenocar-
592cinoma, the addition of an anti-EGFR antibody to first-line standard
593chemotherapy failed to show a significant survival benefit in two
594RCTs (8, 9). Similar negative results were also observed when the
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Figure 5.
Dual EGFR blockade is the most effective treatment in EGFR-amplified PDXs. Tumor growth curves in mice cohorts derived from GTR0060 (A), GTR0110 (C), and
GTR0511 (D) patients treated with the EGFR inhibitors, cetuximab (CETUX), erlotinib (ERL), and lapatinib (LAP), alone or in combination, as indicated. The red lines
indicate the day when treatment was started. The response in mice has been evaluated using RECIST 1.1–like criteria, that is, PD: ≥35% increase from baseline; PR: ≥
50% reduction from baseline; and SD: intermediate variations from baseline. B, Spaghetti plot illustrating drug response in the xenotrial performed on the cohort of
mice derived from GTR0060 PDX. Individual lines represent, for each mouse, the percentage variation in tumor burden, from start of treatment (day 0). Blue lines,
cetuximabþ lapatinib–treatedmice and red lines, cetuximabþ erlotinib–treatedmice. Dashed line indicates treatment stop.E,Westernblot analysis of the activation
state of EGFRand its downstream targets (AKT,MAPK, andS6) inGTR0060 tumor–derived cells treatedwith the indicated drugs/drug combinations. Actinwas used
as loading control. Statistical significance is indicated ( , P <0.01;  , P < 0.001).
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597 small-molecule TKI, gefitinib, was compared with placebo from the
598 second-line setting and beyond (10). Sporadic responses to EGFR
599 inhibitors observed in these trials, however, led several researchers to
600 postulate the existence of a subset of metastatic patients with EGFR-
601 addicted tumors, potentially vulnerable to EGFR blockade (13). The
602 amplification of the EGFR gene is found in 3%–5% of primary
603 gastroesophageal adenocarcinoma tumors (4, 6) and highly correlates
605with poor prognosis (47). By exploiting four different datasets, we have
606shown here that EGFR amplification has similar prevalence and is
607associated with poorer survival in the metastatic setting. This was also
608confirmed in the nonmetastatic setting, by analyzing TCGA data. In a
609prespecified exploratory analysis of one of those datasets, theCOG trial
610randomizing 209 chemoresistant metastatic patients to gefitinib or
611placebo (10) found that EGFR amplification was a positive predictive
Figure 6.
TSC2 inactivation is amechanism of resistance to EGFR-targeted therapies.A, Tumor growth curves in themice cohorts derived fromGTR0078 and treatedwith the
EGFR inhibitors, cetuximab (CETUX), erlotinib (ERL), and lapatinib (LAP), alone or in combination, as indicated. The arrow indicates the day when treatment was
started.B, The table shows the two TSC2mutations identified in GTR0078 PDX. C, Tumor growth curves in themice cohorts derived fromGTR0078 and treated with
erlotinib or the combination erlotinib þ everolimus (ERLþ EVEROL). The red line indicates the day when treatment was started. D, Western blot analysis of the
activation state of EGFR and its downstream targets (AKT, MAPK, and S6) in GTR0078 tumor–derived cells treated with the indicated drugs/drug combinations.
Actin was used as loading control. Statistical significance is indicated ( , P < 0.001).
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614 marker for EGFR targeting, whereas a smaller advantage was
615 observed in patients with chromosome 7 polysomy (13). Response
616 to the anti-EGFR mAb, cetuximab, used alone or in combination
617 with chemotherapy, was reported in a small set of 7 EGFR-amplified
618 patients; albeit the role of the cytotoxic backbone contribution
619 cannot be ruled out in three responders, one response was induced
620 by EGFR blockade alone (48). Such results clearly mirror those
621 achieved in patients receiving panitumumab monotherapy by our
622 study. All together, these observations suggest that EGFR is an
623 oncogenic driver, with potentially exquisite sensitivity to EGFR-
624 targeting drugs, in a small but clinically consistent subgroup of
625 gastroesophageal adenocarcinomas. On the other hand, in these
626 EGFR-amplified tumors, we observed the presence of selected
627 cooccurring driver alterations. Specifically, MET/HER2/KRAS
628 coamplifications and KRAS/PK3CA/PTEN comutations were iden-
629 tified in 53% and 35% of patients in the EGFR-amplified subgroups
630 included in TCGA and the FMI datasets, respectively; this result
631 highlights that only a subset of patients with EGFR-amplified
632 gastroesophageal cancer may significantly benefit from single-
633 agent anti-EGFR therapy. Here, we have, for the first time, func-
634 tionally identified TSC2 mutations as a potential new mechanism
635 conferring resistance to EGFR inhibition in gastroesophageal ade-
636 nocarcinomas. TSC2 is a GTPase-activating protein, whose loss or
637 inactivating mutation results in the constitutive load of Rheb with
638 GTP and activation of mTORC signaling (39). Interestingly,
639 according to cBioPortal, TSC1/TSC2 mutations are significantly
640 associated with EGFR amplification (but not with other RTKs) in
641 gastroesophageal adenocarcinomas, possibly indicating that
642 mTORC constitutive activation can sustain the oncogenic role of
643 EGFR. Our preclinical trial in an EGFR-amplified/TSC2-mutated
644 gastroesophageal adenocarcinoma PDX confirms this hypothesis.
645 The pharmacologic inhibition of TSC2-sustained mTORC activa-
646 tion by everolimus, a clinical-grade small-molecule mTOR inhib-
647 itor, overcame primary resistance and restored sensitivity to EGFR
648 inhibition. Our data are reinforced by a recently published article
649 from Arteaga and colleagues (49), in which they showed that
650 hyperactivation of the mTORC pathway drives resistance to ther-
651 apies targeting another member of the HER family, namely HER2,
652 in HER2-mutant breast cancer. In their work, similarly to what we
653 have observed, the combination of the TORC1 inhibitor, ever-
654 olimus, and neratinib overcame resistance.
655 Resistance is a common occurrence of RTK inhibition across
656 diseases, targets, and drugs. Several cell autonomous mechanisms
657 sustaining resistance to driver RTKs have been identified so far,
658 including mutations of the target itself, activation of downstream
659 transducers, activation of parallel pathways, and transdifferentiation.
660 Moreover, in many cases, the amplified RTK is not located in the
661 natural genomic site, but it is rather extrachromosomal. This results in
662 a mechanism favoring rapid adaptation of cancer cells to environ-
663 mental changes. Indeed, as extrachromosomal DNA lacks centro-
664 meres, it is unequally segregated during cell division, leading to
665 increased tumor heterogeneity and different cellular fitness in diverse
666 contexts. Cancer cells in which oncogenes are extrachromosomal can
667 thus become resistant to RTK inhibitors either by increasing the
668 number of gene copies (thus titrating the amount of the available
669 inhibitor) or by progressively decreasing the number of gene copies.
670 Both themechanisms are sustained by experimental data. For example,
671 Nathanson and colleagues (50) showed that glioblastoma cells can
672 become resistant to erlotinib by eliminating extrachromosomal copies
673 of the mutant EGFR gene. This “adaptation” to the treatment can be
674 acquired and expanded along tumor evolution, enabling tumors to
676maintain their intratumoral heterogeneity. In previous works (51, 52),
677we have shown that inMET-hyperamplified gastric cancer cells (where
678the amplified gene was extrachromosomal), resistance was due to
679further acquisition of gene copies; this resulted in an amount of
680activated receptor overcoming the inhibitory ability of the drugs at
681tolerable doses.
682To bypass primary and prevent secondary resistance to EGFR-
683targeted drugs in EGFR-amplified gastroesophageal adenocarcinomas,
684we leveraged our large platform of 151 primary gastroesophageal
685adenocarcinomas patient–derived mouse avatars (22), enriched for
68615 cases with EGFR gene copy gain, including four avatars with more
687than eight EGFR copies (confirmed as amplified, i.e., nonpolysomic,
688by silver ISH). EGFR inhibition, in absence of chemotherapy,
689resulted in a clinical response in three of four cases. Notably, one
690of these cases featured 12 EGFR copies, a range of amplification that
691is just above the threshold (eight copies) considered biologically
692relevant and that has not been investigated previously (48). Inter-
693estingly, a CR was achieved only in the PDX with the highest EGFR
694CNG, suggesting that a higher level of gene amplification may be
695associated with a greater magnitude of treatment benefit, as it is
696known for HER2-amplified gastroesophageal adenocarcinoma and
697breast cancer (30, 53).
698The pharmacologic space of EGFR-targeted drugs is well populated
699by antibodies and small-molecule TKIs, both experimental and
700approved for use in clinically diverse settings (54, 55).
701In our preclinical trials in EGFR-amplified gastroesophageal ade-
702nocarcinoma avatars, we compared the efficacy of randomly allocated
703TKIs and cetuximab, delivered as single agent or in combinations.
704Erlotinib and cetuximab showed single-agent excellent activity in one
705and two models, respectively, while in a third model, cetuximab
706treatment resulted in disease stabilization. Importantly, however, the
707dual EGFR blockade resulted in a sustained significant response in all
708three models, suggesting that a strong inhibition of the downstream
709transducers is needed to eradicate the disease.
710In conclusion, our study further corroboratesEGFR amplification as
711an actionable therapeutic target in gastroesophageal adenocarcinoma,
712demonstrates that a dual EGFR blockade may be needed to maximize
713the therapeutic efficacy, and identifies potential mechanisms of pri-
714mary resistance, specifically the mTORC pathway, paving the way for
715experimentally driven clinical trials. In fact, the next-generation
716clinical trial landscape in EGFR-amplified gastroesophageal adeno-
717carcinomas may not be at a dead end. The combination of lapatinib
718and cetuximab has already been proven safe in a phase I trial (56),
719potent second-generation antibodies mixtures against different, non-
720overlapping epitopes of EGFR, such as Sym004 and MM-151 (57, 58),
721are into clinical development, and the TORC pathway is targetable
722with commercially available drugs. Given the diversity of clinically
723relevant genomic alterations and lack of benefit from EGFR-targeted
724therapies in unselected gastroesophageal adenocarcinoma popula-
725tions, broad-based genomic profiling is thus necessary to reliably
726detect EGFR gene amplification in addition to other potential drivers
727and mechanisms of resistance.
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